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Abstract
The present work characterizes the mRNA expression of PACAP type I receptors in rat peritoneal macrophages but not
 .in peritoneal lymphocytes by both retrotranscriptase and polymerase chain reaction RT-PCR and homologous Southern
 .hybridization and the stimulation by PACAP27, PACAP38 and vasoactive intestinal peptide VIP of sn-1,2-diacylglycerol
w125 xproduction in rat peritoneal macrophage membranes. The binding of I PACAP27 was time and cell concentration
dependent. Scatchard analysis of displacement of the bound tracer by unlabeled PACAP27 indicates the existence of two
 .  .classes of binding sites. The dissociation constant K was 0.64"0.08 nM and the maximal binding capacity B wasd max
8.85"1.45 fmolr106 cells for the high affinity binding site. The low affinity binding site had a K of 0.10"0.06 mMd
with a B of 300"21.9 fmolr106 cells. Scatchard analysis of VIP displacement data indicated the presence of twomax
classes of binding sites with a K and B different to those of PACAP27. These results suggest that PACAP binds to twod max
binding sites, PACAP type I receptors and PACAP type II receptors. The PACAP27-stimulated diacylglycerol production
was not affected by treatment with pertussis toxin. However, the presence of GTP partially inhibited this PACAP27
stimulation of 1,2-diacylglycerol in a dose dependent manner, although GTP alone stimulates diacylglycerol accumulation.
In conclusion, for the first time we demonstrate by biochemical and molecular biology criteria the existence of PACAP type
I receptors on rat peritoneal macrophages and the evidence for coupling with a pertussis toxin-insensitive G regulatory
protein. q 1997 Elsevier Science B.V.
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1. Introduction
Pituitary adenylate cyclase activating polypeptide
 .38 PACAP38 is an amidated 38 amino acid neu-
ropeptide recently isolated from ovine hypothalamus
on the basis of its ability to stimulate adenylate
w xcyclase in rat anterior pituitary cell cultures 1 .
PACAP27 is an amidated neuropeptide produced by
cleavage of PACAP38 at the dibasic Lys–Arg site in
position 29–30, and subsequent action of an a-
amidating monooxygenase on glycine in position 28
w x2 . PACAP27 has comparable biological activity as
w xPACAP38 on pituitary adenylate cyclase 2 . In rat,
both molecular forms of PACAP probably derive
from the same precursor because a single hybridizing
cDNA has been cloned from rat brain cDNA library
w x3 . PACAP27 exhibits 68% amino acid sequence
 .homology with vasoactive intestinal peptide VIP ,
thereby identifying PACAP as a new member of the
w xVIPrglucagonrsecretin family 4 . Radioimmunoas-
say and immunochemical studies have shown that
these regulatory peptides are widely distributed, be-
ing specially abundant in the central nervous system,
w xadrenal medulla, and testis 4 . The predominant form
is P A C A P 3 8 , a l th o u g h th e r a t io
PACAP38rPACAP27 varies among tissues, suggest-
ing differently processing in different tissues. PACAP
has diverse biological effects that are tissue-specific
w x4,5 . With respect to PACAP on immune system, it
has been described that PACAP inhibits the
mitogen-stimulated proliferation of murine spleno-
w x  .cytes 6 , stimulates the interleukin 6 IL-6 secretion
w xby cultured rat astrocytes 7 , increases the phago-
cytosis of fluorescent latex beads by mouse peri-
w xtoneal macrophages 8 , and inhibits the mobility of
w xmurine thymocytes and splenic lymphocytes 9 . The
existence of PACAP in the central nervous system
and in different peripheral tissues raises the possibil-
ity of a widespread occurrence of specific PACAP
receptors. In this context, two PACAP receptor types
 .have been distinguished so far: 1 the type I receptor
that exhibits a higher affinity for PACAP38 and
 .PACAP27 as compared with VIP and 2 the type II
receptor, which exhibits similar affinity for
w xPACAP38, PACAP27, and VIP 5,10,11 . Several
receptor autoradiography and radioligand-binding
studies have described the tissue distribution for each
type of PACAP receptor. In this context, each tissue
appears to express varying proportions of type I and
type II PACAP receptors. Tissues that contain pre-
dominantly type I receptors include the adrenal gland,
testis, anterior pituitary, hypothalamus, and other
brain regions. Tissues that contain predominantly type
II receptors include lung, liver, prostate gland, and
w xseminal vesicle 12–15 . In the immune system,
w xPACAP receptors were not found in the thymus 15 ,
w xbut they are present in murine splenocytes 6 and
PACAP immunoreactivity was found in central and
w xperipheral lymphoid tissues 16 . In addition to acti-
vation of adenylate cyclase, PACAP can stimulate
phosphatidylinositol hydrolysis and increase cytosolic
2q w xCa in several cell types 17–20 , but it is not yet
clear whether activation of distinct signal transduc-
tion cascades reflects activation of distinct receptor
types.
In the present study, we describe for the first time
by gene expression and by biochemical and func-
tional characterization the presence of PACAP type I
receptors in rat peritoneal macrophages.
2. Materials and methods
2.1. Chemical reagents
Rat PACAP38, PACAP27, and VIP were provided
 .by Peninsula Laboratories Europe Merseyside, UK .
 .Pertussis toxin PTx , bacitracin, leupeptin, pepstatin,
 .phenylmethylsulfonylfluoride PMSF , N -p-tosyl-L-a
 .lysine chloromethyl ketone TLCK , 3-isobutyl-1-
 .  .methyl-xantine IBMX , dithiothreitol DTT , BSA
 .  .fraction V , MgCl Mol Biol Grade , GTP, ATP,2
thymidine, RPMI 1640, phosphocreatine, creatine ki-
nase, EGTA, EDTA, guanidine, DEPC, and agarose
 . w125 xwere from Sigma St. Louis, MO, USA . I -
 .PACAP27 2200 Cirmmol, 81.4 Tbqrmmol and a-
w32 x qP NAD were purchased from New England Nu-
 .clear Du Pont de Nemours, Dreieich, Germany .
w32 xg- P ATP, DAG assay reagent system, and amprep
minicolumns were obtained from Amersham Bucks,
.UK . Plasmid pCAP23 was a generous gift from
Prof. S. Nagata. M-MLV Reverse Transcriptase was
 .from Promega Madison, WI, USA . RNase inhibitor,
  . .random hexamer primers dp N , dATP, dCTP,6
dGTP, dTTP were obtained from Pharmacia LKB
 .Biotechnology AB Uppsala, Sweden . Ampli Taq
DNA polymerase was from Perkin Elmer Cetus
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 . qBranchburg, NJ, USA . NAD , DIG DNA labeling,
DIG Luminescent Detection Kits, EcoRI and PstI
enzymes were from Boehringer Mannheim GmbH
 .Manhein, Germany . Nylon membranes were pur-
chased from Schleider and Schuell Dassel, Ger-
.  .many . Oligo dT cellulose and phenolrwater were
 .from Biotech laboratories Houston, TX, USA and
the primers from Centro de Investigaciones Biologicas´
 .CIB-CSIC, Madrid, Spain . All electrophoresed
 .reagents were from BioRad Hercules, CA, USA .
All other chemicals were of reagent grade.
2.2. Tissue preparation and cell separation for mRNA
expression studies
Male Wistar rats weighting 180–200 g were used.
Animals were killed by decapitation according to the
guidelines by the European Community Council Di-
rectives 86r6091 EEC, the abdomen cleaned with
70% ethanol and the abdominal skin was carefully
dissected without opening the peritoneum, and 10 ml
of PBS buffer was injected intraperitoneally. Then,
the abdomen was massaged and about 90% of the
saline solution was extracted containing the cell sus-
pension. Cells were counted and adjusted in the same
medium at 3=106 cellsrml. Peritoneal lymphocytes
and macrophages were purified by sorting on a
Plus  .FACStar Beckton–Dickinson, San Jose, CA .
Both cell types were distinguished by their different
 .  .forward scatter FS vs. side scatter SS profiles.
Forward scatter is indicative of cell size whereas side
scatter is indicative of cell complexity. In all cases,
cell purities exceeded 98%. Rat cerebral cortex and
kidney were carefully removed from adult rats and
quickly frozen at y708C until RNA isolation.
2.3. RNA extraction, re˝erse transcription and PCR
amplification
Total RNA was extracted from freshly isolated
organs by water saturated phenolrchloroformriso-
 .amyl alcohol 49:49:1 as previously described by
w xChomczynski et al. 21 . mRNA from peritoneal
macrophages and lymphocytes was purified with
 .oligo dT cellulose columns and the amount was
determined spectrophotometrically at 260 and 280 nm.
 .500 ng of poly A -RNA was reversed transcribed in
the following mixture 1.2 mM MgCl , 50 mM KCl,2
10 mM Tris–HCl pH 8.3, 5 mM DTT, 10 mM 2X-de-
oxynucleoside-5X triphosphates, 100 units murine
monkey leukemia virus reverse transcriptase, 66 units
RNase inhibitor and 2 mg hexadeoxynucleotide mix-
 ..ture dpN . The resulting mixture was incubated for6
45 min at 398C and then the sample was heated at
958C for 5 min on a Perkin Elmer Cetus DNA Ther-
mal Cycler 480 and was maintained at 48C until PCR
amplification. To control genomic DNA contamina-
tion, the reaction was regularly performed in the
absence of reverse transcriptase. Primers used for the
amplification of the PACAP type I receptor cDNA
fragment were chosen that seem to encode the N-
terminal extracellular domain of the PACAP type I
w xreceptor gene 22 . The positions were 456 and 739
yielding a 305 bp PCR product, after mRNA RT-PCR
amplification. Their sequences were respectively,
from 5X to 3X, CCAACGACCTGATGGGACTAAA
and CTCAGGCTCATAATCATCAAAC. For PCR
amplification cDNA preparation was added to the
following PCR mix: 50 mM KCl, 10 mM Tris–HCl
pH 8.3, 2.5 units Taq DNA polymerase, 1.2 mM
MgCl and 0.5 mg sense and antisense primers. The2
mix was subjected to the same PCR conditions:
denaturation at 948C for 5 min, 35 repeated cycles of
denaturation at 958C for 1 min, primer annealing at
608C for 1 min and a final extension cycle at 728C for
7 min on a Perkin Elmer Cetus DNA Thermal Cycler
480. Sample using water instead of cDNA no cDNA
.control with specific primers for each PCR reaction
was included to ensure the absence of exogenous
DNA contamination in the PCR reactions.
2.4. Probe preparation
Plasmid pCAP23 has a 900–1000 bp Pst I frag-
ments containing the primary sequence of the rat
PACAP type I receptor cDNA, this fragment was
used as a probe to detect PACAP type I receptor
specific sequences. The isolated DNA fragment was
labelled with a DIG DNA labelling kit and used for
hybridization in Southern blots.
2.5. Southern blot hybridization
After amplification, 10 ml of PCR reaction were
electrophoresed in 2% agarose in Tris–acetate EDTA
 .buffer TAE and visualized by staining with ethid-
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ium bromide and UV illumination using as a size
molecular marker FX 174 DNArHinf I. The PCR
product was transferred to a nylon membrane using a
vacuum blotting apparatus Hybaid LTD, Tedding-
.ton, UK with 20= SSC as a transfer solution. 1=
SSC solution contained 0.15 M NaCl, 0.015 M sodium
citrate. The PCR product was crosslinked to the
nylon membrane using UV light Linus, Cultek SL,
.Spain . Blots were prehybridized at 428C for 4 h in
prehybridization buffer 50% formamide, 5= SSC,
 .2% blocking reagent Boehringer Mannheim GmbH ,
.0.1% N-laurylsarcosine, 0.02% SDS , then, blots were
hybridized at 428C overnight in the same prehy-
bridization solution plus 10 ng DNArml of corre-
sponding labelled probe. Blots were washed twice for
5 min in 2= SSCr0.1%SDS at room temperature
and twice in 0.2= SSCr0.1%SDS for 15 min at
428C. To detect the hybridization signal the blots
were incubated for 30 min in 0.1 M maleic
acidr0.15 M NaClr1% blocking reagent and 30 min
with 1r10 000 anti-DIG-AP anti-digoxigenin conju-
.gated to alkaline phosphatase . Finally, they were
washed and incubated in Lumigen PPD, and the blots
were exposed to Kodak X-OMAT AR film at room
temperature.
2.6. Isolation of peritoneal macrophages and mem-
branes preparation
Peritoneal macrophages were elicited from male
Wistar rats according to the method of Tsunawsky
w xand Nathan 23 . Utmost precautions were taken such
that animals remained free from infection by environ-
mental pathogens. Briefly, Wistar rats body weight
.250–300 g , were injected intraperitoneally 4 days
before harvest with 5 ml 6% sodium caseinate. Ani-
mals were killed by decapitation according to the
guidelines, and immediately, peritoneal cavity was
washed with 2=10 ml of cold 0.15 M NaCl. Cells
were pelleted by centrifugation and then were treated
with 0.2% NaCl for 30 s in ice to lyse red blood cells.
The cell suspensions were washed twice with PBS
buffer containing 5% FBS and finally resuspended in
RPMI 1640 containing 5% BSA and 1 mgrml baci-
tracin, and immediately used for binding studies.
Viability, as determined by trypan-blue exclusion,
was always greater than 95%. Mean cells per rat
varied from 20–30=106 cells, of which 90% were
macrophages, 2–3% were lymphocytes and 7–9%
were polymorphonuclear leukocytes by morphologi-
cal criteria in Giemsa and Papanicolau staining tech-
w xniques 24 . Macrophage membranes were obtained
w xas described previously 25 . Briefly, macrophages
 .were resuspended in 5 mM Hepes pH 7.5 containing
0.1 mgrml bacitracin, 0.01 mgrml leupeptine,
0.01 mgrml TLCK, 0.05 mgrml PMSF, and 1 mM
EDTA. After 15 min incubation at 48C, cells were
 .disrupted by sonication 2=10 s burst. The ho-
mogenate was centrifugated at 600=g for 5 min at
48C, and the supernatant was centrifugated at 30 000
=g for 30 min at 48C. The pellet was resuspended in
 .20 mM Hepes pH 7.4 containing 1 mM PMSF and
was frozen at y808C until used. Proteins were deter-
 .mined with a protein assay kit BioyRad based on
w xthe method of Bradford 26 .
2.7. Binding experimental procedure
 6 .Rat peritoneal macrophages 5=10 cellsrml
w125 xwere incubated with 100 pM I PACAP27 in
 .250 ml, containing 50 mM Tris–HCl, 5% wrv BSA,
1 mgrml bacitracin, pH 7.4, for 45 min at 208C. For
stoichiometric studies, increasing concentrations of
 y11 y6 .native peptide 10 to 10 M were incubated
under the described above conditions. For competi-
tive inhibition studies, increasing concentrations up
.to 0.1 mM of the related peptides were used. At the
end of incubation, cell-bound peptide was separated
by centrifugation, then the supernatant containing the
free radioactivity was rapidly removed by aspiration,
and the pellets were washed twice with RPMI 1640,
 .  .5% wrv BSA containing 15% wrv sucrose. The
cells associated-radioactivity was counted in an LKBg
counter. Specific binding was calculated from total
binding by subtracting non-specific binding, as deter-
mined by binding of tracer in the presence of unla-
beled PACAP27 at 1 mM. Non-specific binding was
about 3% of the total radioactivity added. All data
were analyzed by non-linear least squares curve fit-
ting by LIGAND software. Each individual experi-
ment was performed in triplicate.
2.8. Diacylglycerol assay
DAG production was assayed at 308C, in a final
volume of 200 ml containing 50 mM Tris–HCl, pH
7.4, 2 mgrml BSA, 0.2 mgrml bacitracin, 0.1 mgrml
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leupeptin, 1 mM PMSF. When GTP was present,
1.5 mM phosphocreatine and 0.1 mgrml creatine ki-
nase were also added. The incubation medium was
equilibrated for 3 min at 308C. The assay was initi-
 .ated by addition of the membranes 300 mg . Samples
were assayed by the DAG kinase described by Preiss
w x27 , with a DAG assay reagent system for Amer-
sham, which only measures sn-1,2-diacylglycerol,
which is the physiological activator of PKC. g-
w32 xP Phosphatidic acid from the samples was purified
 .by chromatography Amprep minicolumns and the
final eluate was transferred to scintillation vials with
10 ml of scintillant for counting in a liquid-scintilla-
tion counter.
2.9. Pertussis-toxin treatment of macrophage mem-
branes
The treatment of macrophage membranes with
thiol-preactivated pertussis toxin was carried out as
described by Ribeiro-Neto et al. with some modifica-
w x  .tions 28 . The membrane suspension 300 mg was
incubated in Tris 100 mM pH 8.0 containing 10 mM
NADq, 10 mM thymidine, 100 mM GTP, 1 mM ATP,
1.25 mM MgCl , 1 mM EDTA, 0.6 mgrml creatine2
kinase, 4.5 mgrml phosphocreatine, 1 mM PMSF for
4 h at 308C with or without 2 mg of PTx. After
incubation the membrane suspension was centrifu-
gated and the pellet washed twice and finally resus-
 .pended in Hepes buffer 20 mM, pH 7.4 , containing
bacitracin 0.1 mgrml, 0.1 mgrml leupeptin and 1 mM
PMSF to 1,2-diacylglycerol experiments.
2.10. ADP ribosylation experiments
To demonstrate whether the ADP-ribosylation of
the pertussis-toxin substrate was complete, we per-
formed the radiolabeling by incubating for 45 min at
w32 x q308C with 0.5 mM a- P NAD and preactivated
pertussis toxin as described above, after preincuba-
tion of the membranes for 4 h with or without PTx.
2.11. Western blot analysis
 .Macrophage membranes 50 mg were resolved by
 .12% sodium dodecyl sulfate SDS polyacrylamide
w xgel electrophoresis 29 , and then transferred onto
 .nitrocellulose membranes Hoeffer, CA, USA . Elec-
troblots were probed with either anti-G Duaqr a11
.Pont de Nemours, Germany which recognizes the
carboxi terminus or with anti-b common Du Pont de
.Nemours, Germany which recognizes the carboxi
terminus and were diluted 1:1000 in 50 mM Tris
containing 2 mM CaCl 80 mM NaCl, 0.2% Nonidet2,
40, 0.02% sodium azide and 5% dry milk WB
.buffer , and were used as primary antibody. The
immunoreaction was visualized by an autoradio-
w125 xgraphic method using anti-rabbit Ig, I -labelled
 1. species-specific F ab fragment 5–20 mCirmg an-2
.tibody protein, 200 000 cpmrml in WB buffer .
3. Results
3.1. Gene expression of PACAP type I receptor
Rat PACAP type I receptor expression was exam-
 .ined by polymerase chain reaction PCR after re-
verse transcription of mRNA from rat peritoneal
macrophages and lymphocytes isolated by flow cy-
tometry using oligonucleotide primers specific to the
w xrat PACAP type I receptor 2 . Pairs of oligonucleo-
tides spanning a large part of the extracellular domain
of the rat PACAP type I receptor were used as
  ..primers in the PCR reactions Fig. 1 A . Amplified
products were separated on agarose gels and a band
identical in size to the brain, used as positive control,
was obtained in the peritoneal macrophages Fig.
 ..1 B . This PCR product corresponded to the pre-
 .dicted size 305 bp for PCR amplification using the
PACAP type I receptor as template. However, no
specific band was obtained with mRNA from kidney,
used as negative control, and from isolated peritoneal
  ..lymphocytes Fig. 1 B . In addition, no signal was
detected in negative controls without cDNA Fig.
 . .1 B , lane 5 , or from reactions containing RNA that
 .was not reverse transcribed data not shown . The
specificity of the amplifications was confirmed by
Southern blot hybridization by using a PACAP type I
  ..receptor specific probe Fig. 1 C .
[125 x3.2. Binding properties of I PACAP binding in rat
peritoneal macrophages
w125 xThe specific binding of I PACAP27 to rat peri-
toneal macrophages was a time and temperature de-
 .pendent process Fig. 2, left . The binding of
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 .Fig. 1. Expression of PACAP type I receptor mRNA by rat peritoneal macrophages. A Schematic representation of the RT-PCR strategy
 .used to amplify the rat PACAP type I receptor sequence. The relative positions of the primers box arrows used in the amplifications
 .  .reactions and the pCAP23 probe thick line are shown. The coding region is represented by boxes; the signal peptide SP and
 .  .transmembrane domain I–VII are represented by hatched and black areas, respectively. B Ethidium bromide staining of amplified
cDNA fractionated in agarose gel electrophoresis. Lane 1: brain; lane 2: kidney; lane 3: peritoneal macrophages; lane 4: peritoneal
 .  .lymphocytes; lane 5: negative control no cDNA control . Marker: FX 174rHinf I. C Southern blot analysis using a PACAP type I
receptor mRNA specific probe. Arrows show the predicted size of the amplified cDNA fragment. This result represents four identical
experiments.
w125 xI PACAP27 occurred rapidly and reached the
maximal level at 45 min. The binding remained stable
w125 xfrom 45–120 min at 208C. Binding of I PACAP27
at 378C was lower than at 208C. Little specific bind-
ing was observed at 48C, even after 120 min of
incubation. The rate of binding was more rapid and
high at 208C compared with 308C. The specific bind-
w125 x  2ing of I PACAP27 was a linear function r s
. 60.97 of cell concentration up to 5=10 cellsrml
 .Fig. 2, right . Higher cell concentrations gave bind-
ing values lower than expected, probably due to a
w125 xhigh degradation of I PACAP27.
The com petition of binding betw een
w125 xI PACAP27 and increasing concentrations of un-
labeled PACAP27, PACAP38, or VIP with peritoneal
macrophages are shown in Fig. 3. The total binding
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and non-specific binding of the ligand were approxi-
mately 9% and 3%, respectively, of the total
w125 xI PACAP27 added. PACAP27 in the concentra-
tion range between 10y11 and 10y6 M competitively
w125 x  .inhibited the binding of I PACAP27 100 pM to
 .macrophages; half-maximal inhibition IC was ob-50
tained at 0.77"0.13 nM native PACAP27. When the
stoichiometric data are interpreted by Scatchard anal-
w xysis 30 , a curvilinear plot with upward concavity
 .was obtained Fig. 3, bottom . This curve could be
resolved into two straight lines, suggesting the pres-
ence of two classes of PACAP27 binding sites: a
class with high affinity K s0.64"0.08 nM and lowd
binding capacity 8.85"1.45 fmolr106 cells, and a
class with low affinity K s0.10"0.06 mM and highd
binding capacity 300"21.9 fmolr106. As it is shown
 .in Fig. 3 top , the displacement slopes for bound
w125 xI PACAP27, unlabeled PACAP27, PACAP38, and
VIP were parallel. The order of potency of the differ-
ent peptides, as expressed by the concentration giving
half-maximal inhibition of tracer binding, was as
 .follow: PACAP27 IC s 0.77 " 0.13 nM G50
 . PACAP38 IC s0.89"0.10 nM )VIP IC s50 50
.4.13"0.2 nM . Scatchard analysis for PACAP38 and
VIP also demonstrated the existence of two classes of
Fig. 2. Effect of time, temperature, and cell concentration on
w125 xspecific binding of I PACAP27 to rat peritoneal macrophages.
 . w125 xTime-course left of I PACAP as a function of temperature.
w125 x  .  6I PACAP27 100pM was incubated with cells 5=10
.  .  .  .cellsrml at 48C v , 208C B or 308C ’ . Specific binding
w125 xof I PACAP27 by rat peritoneal macrophages as a function of
 . cell concentrations right . Increasing cell concentrations up to
6 . w125 x  .9=10 cellsrml were incubated with I PACAP27 100pM
at 208C for 45 min. Each point is the mean of triplicates. Two
other separate experiments gave similar results.
w125 xFig. 3. Competitive displacement of I PACAP27 binding to
rat peritoneal macrophages by unlabeled PACAP27, PACAP38,
 .  6 .and VIP top . Cells 5=10 cellsrml were incubated with
w125 x100pM I PACAP27 at 208C for 45min in the absence or
presence of increasing concentrations of unlabeled PACAP27
 .  .  .v , PACAP38 ’ , and VIP l . Results are the means "
SEM of 4 separate experiments. All determinations were made in
triplicate. The Scatchard analysis of displacement of
w125 x  .I PACAP27 binding by unlabeled PACAP27 bottom .
binding sites and the order of K was as follow:d
 .PACAP27GPACAP38)VIP Table 1 .
3.3. Dose- and time-dependence of PACAP27,
PACAP38 and VIP-stimulated DAG production
The effect of PACAP27 on the sn-1,2-DAG pro-
duction from rat peritoneal macrophage membranes
is shown in Fig. 4 as a function of the time. PACAP27
 .0.1 mM in the absence of GTP caused a 2.8-fold
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Table 1
Binding characteristics for PACAP27, PACAP38, and VIP dis-
w125 xplacement of I PAC27 in rat peritoneal macrophages
Peptide IC50 High affinity Low affinity
 .  .K nM K mMd d
B Bmax max
6 6 .  .fmolr10 c fmolr10 c
PACAP27 0.77"0.13 0.64"0.08 0.10"0.06
8.85"1.45 300"21.9
a a aPACAP38 0.89"0.10 0.66"0.04 0.13"0.06
a a9.13"1.13 405"45.2
b b bVIP 4.13"0.2 1.44"0.16 0.15"0.06
b b12.3"3.54 495"56.9
Each point is the means"S.E.M. from four experiments per-
formed in duplicate. Data were statistically analyzed using an
 .analysis of variance ANOVA followed by a Student–
Newman–Keuls multiple range test.
a P )0.05 when comparing vs. PACAP27 values.
b P -0.05 when comparing vs. PACAP27 values.
stimulation of control sn-1,2-DAG production after
 .incubation for 10 min. GTP 100 mM caused a de-
crease on the PACAP27-stimulated production of
 .sn-1,2-DAG about 43%; GTP 100 mM , however,
caused a 1.45-fold stimulation of sn-1,2-DAG.
PACAP27-stimulated production of sn-1,2-DAG was
dose-dependent and monophasic and partially abol-
Fig. 4. Time-course of PACAP27-stimulated production of sn-
1,2-diacylglycerol and effect of GTP. Rat peritoneal macrophage
 .membranes 300 mg were incubated at 308C as described in
Section 2. The reaction was started by addition of the membranes
 .under the following experimental conditions: buffer assay % ,
 .0.1mM PACAP27 v , 0.1mM PACAP27 plus 100 mM GTP
 .  .B , or 100 mM GTP ’ . Results are the values of one experi-
ment representative of three others.
Fig. 5. Dose-dependent response of PACAP27, PACAP38 and
VIP on sn-1,2-diacylglycerol production by rat peritoneal
macrophage membranes. Effect of increasing concentrations of
 .  .PACAP27 v , PACAP38 B , PACAP27 plus 100 mM GTP
 .  .% , or VIP ’ on sn-1,2-diacylglycerol production in rat
 .peritoneal macrophage membranes. Membranes 300 mg were
incubated for 10 min at 308C and the results are the mean of three
separate experiments performed in triplicate.
 .ished by GTP Fig. 5 . The response occurred in the
10y11–10y6 M range of PACAP27 concentrations.
 .Half-maximal stimulation ED was elicited about50
0.97"0.03 nM. There were no significant differ-
ences in ED between PACAP27 and PACAP38,50
however VIP-stimulated production of sn-1,2-di-
acylglycerol showed a ED of 5.2"0.04 nM. GTP50
 .100 mM did not modify the ED of PACAP27, but50
Fig. 6. Effect of NADq pretreatment on pertussis-toxin-cata-
w32 xlysed P ADP-ribosylation in rat peritoneal macrophage mem-
branes. Pertussis-toxin-catalysed ADP-ribosylation of a 39–
 .40 kDa protein. The membranes were pretreated with vehicle y
 . qor pertussis toxin q in the presence of 10 mM NAD and then
washed and further incubated with 2 mg pertussis toxin and
w32 x q0.5mM P NAD . The proteins were separated by SDSrPAGE
and processed by autoradiography. This experiment represents
three others.
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impaired its maximal effect in a dose-dependent man-
ner.
3.4. Pertussis-toxin treatment of rat peritoneal
macrophages membranes and immunodetection of
a q11 and bg subunits
To investigate the nature of the PACAP type I
G-protein coupled receptor in rat peritoneal
macrophage membranes, we examined the PACAP-
stimulated production of sn-1,2-diacylglycerol after
the pretreatment with pertussis-toxin. To demonstrate
that the pertussis-toxin substrate was completely
ADP-ribosylated, the membranes were pretreated with
or without pertussis-toxin for 4 h and then subjected
to pertussis-toxin-catalysed ADP-ribosylation in the
w32 x qpresence of a- P NAD . So, the incorporation of
radiolabel into 40 kDa protein almost completely dis-
appeared after the treatment with pertussis toxin Fig.
.6 . PACAP27-activated sn-1,2-diacylglycerol pro-
duction was not dependent of the pertussis-toxin pre-
 . treatment Fig. 7 , however 100 mM GTP alone 435
Fig. 7. Effect of pertussis-toxin pretreatment on PACAP27 and
GTP stimulated sn-1,2-diacylglycerol production in rat peritoneal
macrophage membranes. Membranes were pretreated with or
 .without pertussis toxin PTx as described in Section 2. The
incubation medium was equilibrated for 3 min at 308C before
addition of 100 mM GTP or 1mM PACAP27. Data were statisti-
 .cally analyzed using an analysis of variance ANOVA followed
by a Student–Newman–Kleuls multiple range test. ) P )0.05
vs. a; )) P -0.05 vs. b.
Fig. 8. Western blot analysis of Gaqr11 and bc subunits.
Membranes from rat peritoneal macrophages were separated by
SDSrPAGE and then transferred to nitrocellulose and immuno-
blotted with SW1 specific antisera against C-terminal of common
beta subunit or QL specific antisera against C-terminal of a11
and q . This experiment is representative of other three experi-11
ments.
."16.9 pmolrmg protein was in part pertussis-toxin
 .sensitive 290"20.8 pmolrmg protein, P-0.05 ,
suggesting that a subunit of PACAP G protein-cou-
pled receptor activate phospholipase C in a way that
is insensitive to Bordetella pertussis toxin. These a
subunits are members of the G family. We used anaq
antibody, which recognizes the carboxyl terminus of
both G and G to detect the presence of a 42 kDaaq a11
 .protein Fig. 8 in rat peritoneal macrophage mem-
branes. The fact that GTP-stimulated production of
sn-1,2-diacylglycerol was partiality pertussis-toxin
sensitive, may be indicated that bg complexes can be
regulated the sn-1,2-diacylglycerol production in rat
peritoneal macrophage, so, we immunodetected a
36 kDa protein with an antibody against the b com-
mon subunit.
4. Discussion
Recent evidence suggests that at least three types
of PACAP receptors are present in mammalian tis-
sues and cell lines. According to the classification of
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w xShivers et al. 15 , type I receptors are the highly
selective PACAP receptors that recognize both
PACAPs with the same high affinity, but has a 300-
to 1000-fold lower affinity for VIP; this receptor is
found in anterior pituitary, brain, astrocytes, neurob-
lastoma cells, adrenal cells, the rat pancreatic cancer-
w xous cell line AR 4-2J, and liver membranes 5 . Type
II receptors are non-selective PACAP receptors
showing the same high affinity for PACAP27,
PACAP38 and VIP. These receptors correspond to
the previously described high affinity VIP receptor,
and it predominates in liver, lung, pancreatic mem-
branes and lymphoid cells and is present in a lower
density than the type I receptor in brain membranes
w x5,31 . Finally, it has been documented a third type of
PACAP binding site, that has been identified as the
VIP type II receptor, and it binds both PACAPs and
w xVIP with a similar high affinity 32,33 .
This paper provides evidence for the first time, by
means of a number of well biochemical and molecu-
lar biology stablished criteria, the existence of a
functional type I PACAP receptors in rat peritoneal
macrophages. In the present report, we demonstrated
the mRNA expression of type I PACAP receptor in
rat peritoneal macrophages, but not in lymphocytes,
using RT-PCR analysis and hybridization with a spe-
cific labelled probe.
Kinetic and stoichiometric studies showed that
PACAP27 binding reaction depended on time and
temperature, and was specific. Based on the results
w xobtained from Scatchard analysis 30 of the binding
data, two independent classes of PACAP27 receptors
can be defined in rat peritoneal macrophages: a class
 .with high affinity K s0.64 nM , and another withd
 .low affinity K s 100 nM . In this study,d
w125 xI PACAP27 was used exclusively in the experi-
ments of competitive displacement, because
PACAP27 has a lower non-specific binding that
w xPACAP38 12 . Schatchard analysis for PACAP38
and VIP also demonstrated the existence of two
classes of binding sites with the following order of
potency for the high affinity binding sites: PACAP27
GPACAP38)VIP. However, both PACAPs and
VIP showed the same potency for the low affinity
binding sites. Although it was previously reported
that PACAP27 and PACAP38 bind at high affinity to
an only receptor in the hypothalamus, anterior pitu-
w xitary, and cultured astrocytes 12,14,34,35 with dis-
sociation constant of about 0.1–0.5 nM, the heteroge-
neous pattern described in our study is in agreement
with the results obtained in some peripheral tissues,
w xsuch as liver and lung 15 where it has been de-
scribed two binding sites for PACAP27 with a Kd
and receptor number similar to those reported in this
w xwork. Similarly as Shivers and colleagues 15 have
previously suggested, it could be possible, in our
system, that high affinity PACAP-binding sites are
identical to the selective type I PACAP receptors.
The binding data seem to indicate that PACAP type I
receptor levels might be lower than PACAP type II
receptors, this may be probably due by the fact that
PACAP type II receptors obscure the lower amount
of PACAP type I receptors. Because there is no
ligands, up to date, which can clearly distinguish the
PACAP type I receptor, further analysis is required
by quantitative Western blot using specific antibodies
against PACAP type I and PACAP type II receptors
in order to know which is the level of every type of
protein in rat peritoneal macrophages. Since several
years ago, it is well stablished using biochemical and
pharmacological approaches, the presence of VIP
w xreceptors in lymphocytes 31,36,37 and in
w xmacrophages 38,39 . Recently, we have described
VIP receptor expression in rat peritoneal macrophages
w xand lymphocytes by RT-PCR analysis 40 . These
VIP receptors are linked to activation of adenylate
cyclase and elevation of intracellular cAMP levels
w x41–43 .
We also found that PACAP27, PACAP38 and VIP
induce a dose-dependent increase in diacylglycerol
production with the same order of potency:
PACAP27 G PACAP38 ) VIP. It is likely that
PACAP was unable to achieve steady state binding
and that this kinetic problem is responsible for the
steep dose-effect curve of diacylglycerol increase.
After 10 min of incubation, the VIP-dose response
curve was parallel to those of both PACAPs. The
IC value obtained for both PACAPs and VIP in50
binding studies was very similar to the ED value on50
diacylglycerol production. These data reflect an effi-
cient coupling of the receptor to the phospholipase C
system and that there was no amplification process
and as well as that there is no receptor reserve for
phospholipase C activation. Taken together, these
data indicate that activation of type I PACAP recep-
tors in rat peritoneal macrophages cause stimulation
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by PACAP27, PACAP38, or VIP of a phospholipase
C pathway. PACAP has previously been found to
stimulate inositol phosphate turnover in various cell
w xtypes, including porcine chromaffin cells 44 , rat
w xpituitary gonadotrophs 45 , gonadotrope-derived
w xaT3-1 cell line 46 , human neuroblastoma cells
w x  . w x19,47 , rat pheochromocytoma PC12 cells 18 , and
w xrat cerebellar neuroblasts 20 . The molecular cloning
of the type I PACAP receptor has shown that the
protein belongs to the seven transmembrane domain
w xG protein-coupled receptor superfamily 48–50 and
revealed the existence of at least five splice variants
differing in the C-terminal end of the third intra-
w xcellular loop 50 , a domain that plays a crucial role
for coupling to various G protein. One of these
variants is specifically coupled to adenylate cyclase,
whereas all other variants are simultaneously coupled
to adenylate cyclase and phospholipase C. Moreover,
evidence suggests that PACAP stimulates adenylate
cyclase activity in several systems through G pro-s
w xtein-coupled PACAP receptor 4,5 . It has been shown
recently that PACAP receptor stimulates the inositol
w xphosphate formation in rat cerebellar neuroblast 20 ,
w xin smooth muscle 51 as well as in rat prostatic
w xepithelium 52 via pertussis toxin-sensitive G pro-
teins, pointing to a G - but not a G -dependent mech-i s
anism. The present study reveals that PACAP27 stim-
ulates diacylglycerol production by a pertussis toxin-
insensitive mechanism. However, stimulation of dia-
cylglycerol by GTP was pertussis toxin-sensitive.
This fact and the detection of the bg subunit could
suggest an implication of the bg subunits in the
regulation of the production of diacylglycerol by
PACAP in rat peritoneal macrophages. In this sense,
for a long time, the prevalent hypothesis for the
mechanism of G protein-mediated signal transduction
was that G subunit is implicated in the regulatorysa
activity of the G protein complex, because its capac-
ity to binding and to hydrolyze GTP, as well as, to
interact with the effectors, while the bg subunits
have been exclusively considered as a regulatory
component of G subunit, stabilizing the a-GDPsa
complex and anchoring the G protein trimer to mem-
brane. Actually, there is increasing evidence that
shows the ability of bg subunit to interact with
receptors as well as with effectors, showing an active
w xrole in the signal transduction 53–56 . It has been
found that bg complex directly interacts with adeny-
w x w xlate cyclase 57,58 , phospholipase Cb 59 , calmod-
w x w xulin 55 , b-adrenergic receptor kinase 60 and cal-
w xcium channels 61,62 and also probably with mus-
q w x w xcarinic K channels 63 , phospholipase A 64 and2
phosphoinositide-3-kinase. Moreover diversity of b
and g subunits predicts that the structural and func-
tional definition of heterotrimers may be more com-
plicated. If all known components can interact with
each other, the number of potential regulatory path-
ways could be vast. On the other hand, the a subunit
of G and its homolog, a , activate all the threeq 11
 .PLCb isoenzymes b , b , b . Thus all three en-1 2 3
zymes are potential effectors for pertussis-toxin in-
sensitive regulation and these three b isoenzymes can
w xalso be activated by purified bg subunits 65 . The
results indicate that all the known isoforms of mam-
malian PLC b can be regulated at unique sites by
both a and bg subunits. Immunoprecipitationqr11
experiments of G-protein-PACAP type I receptor
complexes are in progress to determine the G protein
subunits that act like a signal mediator of the PACAP
type I receptor and immunodetection of the different
PLC isozymes present in rat peritoneal macrophages.
From a physiological point of view, the signifi-
cance of the coupling of PACAP receptors to two
transduction pathways in immune system remains
unknown. Several studies have been reported for the
effect of PACAP on immune cells. In particular,
PACAP stimulates phagocytic functions of rat peri-
toneal macrophages through binding to type I PACAP
w xreceptor and PKC activation 66 . Interestingly, the
maximum effect of PACAP on these actions was
found at 1 nM, which corresponds to the K of thed
high affinity binding sites and to the ED of sn-di-50
acylglycerol production described for PACAP in this
study. However, the inhibitory effect of PACAP de-
scribed on mitogen-stimulated lymphocyte prolifera-
w xtion 6 , on spleen and thymus lymphocyte mobility
w x9 , on thymocyte apoptosis induced by glucocorti-
w xcoids 67 and on chemotaxis and adherence of peri-
w xtoneal lymphocytes 66 was exerted through eleva-
tion of intracellular cAMP levels by binding to VIP
 .receptor type II PACAP receptor .
Taken together, these data support the concept
that, in immune cells, PACAP may binds to two
different binding sites, i.e., VIP receptor type II
.PACAP receptor and type I PACAP receptor, which
correspond to functional receptors positively coupled
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to adenylate cyclase and phospholipase C, respec-
tively.
Therefore, PACAP may play multiple roles in the
control of the immunological and phagocytic func-
tions of immune cells.
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